THEME: "Exploring the Challenges in Pre & Post Formulations and Drug Delivery Systems"
21-22 Mar 2022 
MENA Plaza Hotel Albarsha, Dubai, UAE With a triumph success of previous editions, Scholars Conferences proud to announces its “4th Edition of Scholars International Conference on Pharmaceutics and Drug Delivery Research” (Pharmaceutics 2022) scheduled during March 21-22, 2022 at Dubai, UAE. Pharmaceutics 2022 aims at sharing new ideas and technologies amongst the professionals, industrialists and students from research areas of Formulation Design and Drug Delivery to share their recent innovations and applications and indulge in interactive discussions.
Pharmaceutics 2022 is the apex body representing the World Pharmacists working in various capacities, viz, Community Pharmacists, Hospital Pharmacists, in Industry (in Production, R&D, Quality Assurance Marketing, Regulatory Affairs) Academics and other disciplines and areas of work.
The Conference will also have a space for companies and/or institutions to present their services, products, innovations and research results. Pharmaceutics 2021 involves the tracks like Drug Delivery Technologies, Novel Drug Delivery Systems, Routes of Drug Administration, Pharmaceutical Nanotechnology, Nucleic Acid Based Drug Delivery, Smart Drug Delivery Systems, Nano Pharmaceutics and Advanced Drug Delivery, Bio therapeutics as Novel Technique in Drug Delivery, Drug Delivery and Device Development, Major Challenges in Drug Delivery, Peptide and Protein Drug Delivery, Drug Delivery Equipment and Machinery, Business Opportunities in Drug Delivery, Vaccine Based Drug Delivery Technology, Drug Delivery and Device Development.
The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases. Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing. Pharmaceutical drugs are intended for human or veterinary use presented in their finished dosage form.
Pharmaceutics 2022 will be an interdisciplinary platform for Keynote lectures, Oral or poster presentations, workshops /symposia, and meeting researchers from all around the world, for making professional contacts, to create new opportunities and new collaborations.
The pharmaceutical drug delivery technology market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for pharmaceutical drugs largely in infectious application.
Pharmaceutics Conferences | Best Pharmaceutics Conferences | Drug Delivery Conferences | Best Drug Delivery Conferences | Formulations Conferences | Drug Delivery Webinar | Nanomedicine Webinar | Scholars Conferences
With
the global and regional economic environment changing rapidly owing to the
increasing competition between the countries of the world, attending an international conference in Dubai has
become one of the best ways for young researchers, scientists, scholars, and
academicians living across the United Arab Emirates to present their
groundbreaking research studies and acquire new information. These conferences
provide delegates with the latest market forecasts, industry-leading
information, and analysis, as well as critical insight into the latest
technology to facilitate more efficient and sustainable research studies.
Tourist
Attractions:
Marinomed
Biotech AG
Marinomed is an
Austrian Biotech company specializing in the development of innovative products
based on its IP-protected technology platforms. Under the brand Solv4U,
Marinomed provides Marinosolv® formulation development in technology
partnerships for active ingredients at all stages of drug discovery and
lifecycle extension. Marinosolv® enables
the solubilization and bioavailability of small molecules and peptides hardly
soluble in aqueous formulations. Consequently, new treatments of a multitude of
diseases can be envisaged. Marinosolv® technology facilitates efficient drug
delivery with a low systemic off-target activity. Exsting drugs and off-patent active ingredients can be improved and
re-patented as part of new formulations using Marinosolv®. It has been
clinically shown that Marinosolv® allows a pronounced reduction in the amount
of an API in a formulation with an improved therapeutic effect suggesting a
more targeted, more precise, and more sustainable treatment compared to
existing options. The development of hydrophobic highly active compounds is
often hampered by their low local and systemic bioavailability resulting in
excessively high dosing of the drug to compensate for the lack of efficacy.
Solv4U partnerships address this inherent challenge in drug development and
rely on a clinically proven technology. Formulations based on Marinosolv® are
well-tolerated when administered locally or systemically allowing various
applications in different indications. The patented Marinosolv® technology
offered to Solv4U partners is based on micelles and is customized for
individual compounds to achieve an optimal formulation.
Introduction: The incidence of megaloblastic anemia (MA) has
increased for the last two decades, particularly in underdeveloped countries. This
study aims to determine the association between MA and psychosis among
psychotic patients in the Mental Health Hospital at Taif, Saudi Arabia. Method:
A Fifty psychotic male patients, aged 48.58±1.72, were recruited from the
Mental Health Hospital at Taif, Saudi Arabia, in addition to fifty-four
sex-matched healthy controls. The following tests were run CBC, LFT, VitB12,
Folate, and CRP levels. All data were statistically analysed using the IBM SPSS
Statistics for Windows.Results: The CBC results showed that RBCs count,
hemoglobin, hematocrit, platelets count, MPV, and absolute lymphocyte count
were significantly lower in psychotic patients versus healthy control (P=
0.007, P= 0.002, P= 0.001, P= 0.004, P= 0.0001, and P= 0.005, respectively). In
contrast, the Eosinophil absolute count and Basophil percentage were significantly
higher in psychotic patients (P= 0.009, P = 0.0001, respectively). C-reactive
protein was significantly higher in psychotic patients (P= 0.003). Albumin was
significantly lower in psychotic patients (P= 0.0001). Vitamin B12 levels were
slightly lower in psychotic patients than in the healthy group, although it is
not statistically significant. There were significant negative correlations
between serum levels of VitB12 and Negative symptoms (r= -0.381, P =0.006) and
Hallucination
(r=-0.297,P=0.036).Conclusion: These findings indicate no link between MA induced by VitB12 insufficiency and psychosis among psychotic patients in Taif's Mental Health Hospital. However, low serum VitB12 can predict the severity of some psychosis signs, including hallucinations and negative symptoms.
Recent Publications
1. Fahad Alqarni, Hala S. Eweis, Ahmed Ali, Aziza Alrafiah ,Mohammed Alsieni, Shahid Karim and Mosleh Ayed Alkathyri (2022) The Effect of Coenzyme Q10 on Liver Injury Induced by Valproic Acid and Its Antiepileptic Activity in Rats, Biomedicines. 10, 168.
2. Aziza Al-Rafiah,
Rania Magadmi, AbdulAziz Al-Kaabi, and Nimah Alsomali , Parkinson’s
Disease-Related Biomarkers That May Appear in Amphetamine Abusers, (2021) BioMed
Research International.
3. Aziza Alrafiah
(2021) Secondary Cerebellar Cortex Injury in Albino Male Rats After MCAO: A
Histological and Biochemical Study. 9, 1267.
4. Aziza
Alrafiah, Ebtisam Alofi ,
Yasser Almohiani, Abdullah Hammami ,Talal Qadah,Nora Hakami ,Safa Almaghrabi ,
Moafaq Alrowili and Hytham Altyab (2021) Angiogenesis biomarkers in ischemic
stroke patient. Journal of Inflammation Research. 14 4893–4900
5. Hadeel Alsaegh, Hala Eweis , Fatemah Kamal and Aziza Alrafiah (2021) Celecoxib Decrease
Seizures Susceptibility in a Rat Model of Inflammation by Inhibiting HMGB1
Translocation. Pharmaceuticals. 14, 380.